(Adnkronos) - "Il via libera di Aifa alla rimborsabilità di una nuova terapia orale (deucravacitinib) per la psoriasi in forma moderata o severa è un risultato molto importante. Questa molecola consente di curare e cercare di gestire i sintomi per più tempo possibile e avere nuove opportunità quando le terapie precedenti falliscono di mantenere la risposta. Deucravacitinib è la prima terapia orale ad agire sulla proteina TIK2, che ha un importante ruolo nella regolazione del sistema immunitario. I dati a quattro anni confermano sia la durata della risposta sia il profilo di safety, è una molecola molto ben tollerata”. Lo ha detto Cosimo Paga, executive country medical director Bristol Myers Squibb, in occasione della conferenza stampa di annuncio del via libera da parte di Aifa alla rimborsabilità di deucravacitinib per il trattamento della psoriasi da moderata a severa.
Category
🗞
NewsTranscript
00:00The commitment of Bristol was born for psoriasis about 10 years ago with the Deo Cravasitinib
00:10that we studied in great detail and that today we are happy to be able to announce the reimbursement
00:18for the treatment of adult patients with moderate and severe psoriasis and who are
00:24candidates for systemic therapy. In the field of immunology, however, we are proud
00:31to be able to claim the fact of being pioneers in this field and of having studied the immune system
00:37very thoroughly , so much so that we have been able to develop molecules both for
00:42the treatment of autoimmune diseases where it is important to modulate and try to reduce
00:47the immune response and in the treatment of oncological and hematological pathologies
00:52where it is important to stimulate the activity of the immune system. Deo Cravasitinib is an
00:58oral therapy that acts on a protein on which none of the therapies, even numerous,
01:05that are available to patients, act and we are talking in particular about the protein TIK2 which
01:11has an important role in regulating the immune system. The data confirm the fact that it is a
01:20very active molecule, so much so that we have already given to four years that show both the
01:26duration of the important response and the profile of safety which has shown to be a
01:35very well tolerated molecule. In the field of psoriasis, however, it is very important for patients to
01:40have an additional therapeutic opportunity as psoriasis is cured but unfortunately it is not
01:47cured, so they are patients who have a very long history of disease and it is important to be able to
01:54have new opportunities to cure and try to manage the symptoms for as long as possible and
02:03have new opportunities when previous therapies fail to maintain the response.